Table 2.

Fasting Glucose and Insulin Levels and Kg and Sensitivity Parameters Derived From IVGTT Data in Placebo, ImE, and DE Groups

	Fasting Glucose ± (mg/dL) SEM		Fasting Insulin (µIU/mL) ± SEM		Kg Slope of 10’–40’ (%/min)		ISI (hr * mmol − 1)		ISI % Change Baseline
Group	Placebo + DE	ImE	Placebo + DE	ImE	Placebo + DE	ImE	Placebo + DE	ImE	Placebo + DE	ImE
n	15	7	15	7–8	13–15	7–8	14–15	7	13–114	6–8
Month
0	54.93 ± 1.81	55.71 ± 3.20	17.81 ± 2.563	13.97 ± 4.85	4.56 ± 0.33	4.75 ± 0.36	0.387 ± 0.03	0.618 ± 0.09	0	0
6	61.50 ± 2.62	55.75 ± 2.70	28.46 ± 4.97	20.85 ± 7.81	3.29 ± 0.35	4.14 ± 0.39	0.376 ± 0.04	0.550 ± 0.10	−0.602 ± 12.7	−10.73 ± 8.4
	57
12	57.73 ± 2.64	57.75 ± 2.74	35.88 ± 7.07	41.88 ± 22.92	3.11 ± 0.22	3.92 ± 0.22	0.300 ± 0.04	0.494 ± 0.12	−26.18 ± 13.2	−23.34 ± 14.3
18	59.15 ± 2.46	59.38 ± 3.64	50.23 ± 6.57	54.53 ± 29.16	3.10 ± 0.22	3.59 ± 0.38	0.174 ± 0.2	0.330 ± 0.08	−53.66 ± 4.5	−44.57 ± 10.3
24	73.62 ± 6.58	67.88 ± 5.69	66.39 ± 11.19	46.73 ± 15.27	2.78 ± 0.29	3.75 ± 0.39	0.199 ± 0.3	0.357 ± 0.07	−44.76 ± 7.6	−41.84 ± 10.1
2-way ANOVA
Interaction	P = 0.83		P = 0.82		P = 0.77		P = 0.96		P = 0.93
Time	P = 0.0015		P = 0.0035		P = 0.002		P < 0.0001		P < 0.0001
Treatment	P = 0.39		P = 0.56		P = 0.0004		P < 0.0001		P = 0.88

	Placebo	DE	ImE	Placebo	DE	ImE	Placebo	DE	ImE	Placebo	DE	ImE	Placebo	DE	ImE
n	6	7	7	6	7	6	6	7	7	6	7	7	6	6	7
Month
30	69.33 ± 3.81	67.71 ± 2.67	71.86 ± 5.31	56.28 ± 12	57.95 ± 17.4	30.19 ± 4.75	2.36 ± 0.55	2.89 ± 0.50	3.29 ± 0.44	0.197 ± 0.38	0.239 ± 0.05	0.30 ± 0.05	−42.9 ± 10.4	−51.19 ± 6.05	−50.58 ± 7.34
One-way ANOVA	P = 0.76			P = 0.11			P = 0.33 (K-W)			P = 0.27 (K-W)			P = 0.74

Placebo + DE indicates data from the combined placebo and DE groups that had empty Silastic implants for 24 months, before the DE group was placed on E treatment for the last 6 months of the study.

Abbreviation: K-W, Kruskal-Wallace nonparametric ANOVA.